Form 4: Intellia Therapeutics Exec Sells Shares Under 10b5-1 Plan

Intellia Therapeutics EVP and CFO Edward J III Dulac sold 4,677 shares of common stock for $18 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Edward J III Dulac, EVP and Chief Financial Officer of Intellia Therapeutics, Inc., reported a transaction on July 2, 2026.
• The transaction involved the sale of 4,677 shares of common stock.
• The sale was executed at a price of $18 per share.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on September 8, 2025, which is designed to satisfy affirmative defense conditions for the purchase or sale of equity securities.
• Following the transaction, Mr. Dulac beneficially owns 156,286 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative event due to the sale of shares by a key executive, despite being executed under a pre-arranged plan.

Negatives

• A significant number of shares were sold by a key executive.

Risks

• The sale of shares by a high-ranking executive could be interpreted negatively by the market, potentially impacting investor confidence.
• While executed under a 10b5-1 plan, the sale represents a reduction in the executive's direct beneficial ownership.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports a past transaction by an executive.

Industry Context

StockSavvy.ai notes that insider sales, even under a 10b5-1 plan, can sometimes be perceived by the market as a signal of reduced confidence from management, although the plan's existence mitigates this to some extent by indicating pre-planned diversification or liquidity needs.

Stakeholder Impact

• Shareholders: May view the sale by a key executive with some concern, although the 10b5-1 plan provides a degree of reassurance.
• Employees: Similar to shareholders, may interpret the sale as a potential signal, though the pre-planned nature is a mitigating factor.
• Creditors: Unlikely to be directly impacted by this specific insider transaction.

Next Steps

• Monitor future Form 4 filings for any additional insider transactions.
• Observe market reaction to this reported sale.

Key Dates

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Edward J III Dulac, CFO, Beneficial Ownership